TLR9 and common variable immunodeficiency: If so, treatment with the TLR9-ligands CpG-oligodeoxynucleotides (CpG-ODN) alone or with RA would increase mutation load and possibly tumorigenesis in B cell from both healthy subjects and CVID patients.